Loading
Prostate Cancer Diagnosis and Treatment · Journal article
BMC Urology · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a retrospective case series of 12 carefully selected patients undergoing simultaneous robot-assisted radical prostatectomy and transurethral bladder tumor resection, with no major postoperative complications and no intravesical recurrence observed over a median 48-month follow-up. The authors explicitly state these are preliminary descriptive data and do not constitute evidence of oncological equivalence to staged management, limiting generalizability and strength of inference.
Retrospective single-center case series. Twelve men with clinically localized prostate cancer and concomitant non-muscle-invasive bladder cancer (Ta/T1, papillary) seen at a single center.. Intervention: Simultaneous robot-assisted laparoscopic radical prostatectomy and transurethral resection of bladder tumor. n = 12. Single center (location not specified).
Twelve men enrolled with median age 69 years; 10 of 12 (83.3%) had solitary bladder tumors measuring 1–3 cm Pathologic grade was low in 11 patients (91.7%); 10 patients (83.3%) had stage Ta and 2 (16.7%) had T1 disease For prostate cancer, 6 patients (50.0%) were high-risk per NCCN criteria; 1 patient (8.3%) had positive surgical margin
No control group or comparison to staged management; cannot assess oncological equivalence or relative safety
While the safety profile and absence of recurrence in this small series is encouraging, the highly selected cohort (83.3% stage Ta, 91.7% low-grade) and lack of comparison to staged management mean these findings should not yet guide clinical decision-making. Larger, controlled trials comparing simultaneous versus staged approaches are needed before practice change.
Single-center case series of 12 highly selected patients with no control group, reporting feasibility and descriptive outcomes rather than comparative effectiveness or hard oncological endpoints.
As stated by the source record.
Quoted from the source exactly as published.
While the safety profile and absence of recurrence in this small series is encouraging, the highly selected cohort (83.3% stage Ta, 91.7% low-grade) and lack of comparison to staged management mean these findings should not yet guide clinical decision-making. Larger, controlled trials comparing simultaneous versus staged approaches are needed before practice change.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
To describe the feasibility and mid-term outcomes of simultaneous robot-assisted laparoscopic radical prostatectomy (RALP) and transurethral resection of bladder tumor (TURB) in patients with localized prostate cancer and concomitant non–muscle-invasive bladder cancer (NMIBC). We retrospectively reviewed patients who underwent simultaneous RALP and TURB between 2020 and 2023. Candidates had clinically localized prostate cancer and cystoscopically visible papillary Ta/T1 NMIBC without carcinoma in situ. Patients with findings suspicious for muscle-invasive bladder cancer on preoperative magnetic resonance imaging were excluded. Clinicopathologic characteristics, postoperative findings, and intravesical recurrence were summarized descriptively. Twelve men were included. Median age was 69 years (interquartile range, 64.75–74.00). Bladder tumors were solitary in 10 patients (83.3%) and measured 1–3 cm in 9 (75.0%). Pathologic grade was low in 11 patients (91.7%), and no patient had carcinoma in situ. Pathologic stage was Ta in 10 patients (83.3%) and T1 in 2 (16.7%). Postoperative intravesical therapy consisted of gemcitabine in 8 patients (66.7%) and bacillus Calmette–Guérin in 4 (33.3%). For prostate cancer, 6 patients (50.0%) were classified as high risk according to NCCN criteria (Version 4.2023), and 1 patient (8.3%) had a positive surgical margin. Median length of hospital stay and catheter duration were both 7 days. Cystography on postoperative day 7 showed no urinary leakage. No postoperative complications or readmissions occurred. During a median follow-up of 48 months, no intravesical recurrence or progression to muscle-invasive bladder cancer was observed. In this small, highly selected case series, simultaneous RALP and TURB was technically feasible, with no observed intravesical recurrence during mid-term follow-up. These findings should be interpreted as preliminary descriptive data rather than evidence of oncological equivalence to staged management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.